Study of rivaroxaban for venous thromboembolism prophylaxis after lower extremity fractures in Russian clinical practice
- Authors: Belov M.V.1
-
Affiliations:
- Yaroslavl State Medical University
- Issue: Vol 25, No 1 (2018)
- Pages: 47-51
- Section: Articles
- URL: https://ogarev-online.ru/0869-8678/article/view/47169
- DOI: https://doi.org/10.17816/vto201825147-51
- ID: 47169
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Mikhail V. Belov
Yaroslavl State Medical University
Email: micbelov@yandex.ru
Cand. med. sci., Head of orthopaedic department; assistant professor, chair of traumatology and orthopaedics Yaroslavl’, Russia
References
- Lapidus L., Ponzer S., Pettersson H., de Bri E. et al. Symptomatic venous thromboembolism and mortality in orthopaedic surgery - an observational study of 45 968 consecutive procedures. BMC Musculoskelet Disord. 2013; 14: 177. doi: 10.1186/1471-2474-14-177.
- Российские клинические рекомендации «Профилактика венозных тромбоэмболических осложнений в травматологии и ортопедии». Травматология и ортопедия России. 2012; 1 (приложение): 2-24.
- Jameson S.S., Augustine A., James P. et al. Venous thromboembolic events following foot and ankle surgery in the English National Health Service. J. Bone Joint Surg. Br. 2011; 93 (4): 490-7. doi: 10.1302/0301-620X.93B4.25731.
- Geerts W.H., Bergqvist D., Pineo G.F. et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008; 133 (6 suppl): 381S-453S.
- Eriksson B.I., Borris L.C., Friedman R.J. et al.; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 2008; 358 (26): 2765-75. doi: 10.1056/NEJMoa0800374.
- Kakkar A.K., Brenner B., Dahl O.E. et al.; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372 (9632): 31-9. doi: 10.1016/S0140-6736(08)60880-6.
- Lassen M.R., Ageno W., Borris L.C. et al.; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 2008; 358 (26): 2776-86. doi: 10.1056/NEJMoa076016.
- Turpie A.G.G., Lassen M.R., Davidson B.L. et al.; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373 (9676): 1673-80. doi: 10.1016/S0140-6736(09)60734-0.
- Eriksson B.I., Dahl O.E., Rosencher N. et al.; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370: 949-56.
- Eriksson B.E., Dahl O.E., Huo M.H. et al.; RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). Thromb. Haemost. 2011; 105: 721-9.
- Eriksson B.I., Dahl O.E., Rosencher N. et al.; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost. 2007; 5: 2178-85.
- Ginsberg J.S., Davidson B.L., Comp P.C. et al. for the RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty. 2009; 24: 1-9.
- Lassen M.R., Raskob G.E., Gallus A. et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 2009; 361: 594-604.
- Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Hornick P. and the ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010; 375: 807-15. doi: 10.1016/S0140-6736(09)62125-5.
- Lassen M.R., Gallus A., Raskob G.E. et al. for the ADVANCE-3 investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N. Engl. J. Med. 2010; 363: 2487-98. doi: 10.1056/NEJMoa1006885.
- Lassen M.R., Haas S., Kreutz R. et al. Rivaroxaban for thromboprophylaxis after fracture-related orthopedic surgery in routine clinical practice. Clin. Appl. Thromb. Hemost. 2016; 22 (2): 138-46. doi: 10.1177/1076029615607303.
- Balducci L. Epidemiology of anemia in the elderly: information on diagnostic evaluation. J. Am. Geriatr. Soc. 2003; 51 (3 Suppl): S2-S9.
- Еськин Н.А., Деркач Е.В., Пядушкина Е.А. Клинико-экономический анализ применения эноксапарина, ривароксабана и дабигатрана для профилактики венозных тромбоэмболий у пациентов после больших ортопедических операций. Вестник травматологии и ортопедии им. Н.Н. Приорова. 2016; 4: 28-33.
Supplementary files
